Pharming Group N.V (PHAR) Income from Continuing Operations: 2018-2024
Historic Income from Continuing Operations for Pharming Group N.V (PHAR) over the last 7 years, with Dec 2024 value amounting to -$12.0 million.
- Pharming Group N.V's Income from Continuing Operations rose 1255.41% to $90.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $112.8 million, marking a year-over-year increase of 495.63%. This contributed to the annual value of -$12.0 million for FY2024, which is 283.16% down from last year.
- According to the latest figures from FY2024, Pharming Group N.V's Income from Continuing Operations is -$12.0 million, which was down 283.16% from -$3.1 million recorded in FY2023.
- In the past 5 years, Pharming Group N.V's Income from Continuing Operations ranged from a high of $37.7 million in FY2020 and a low of -$12.0 million during FY2024.
- Over the past 3 years, Pharming Group N.V's median Income from Continuing Operations value was -$3.1 million (recorded in 2023), while the average stood at $2.5 million.
- Its Income from Continuing Operations has fluctuated over the past 5 years, first skyrocketed by 418.42% in 2022, then tumbled by 283.16% in 2024.
- Over the past 5 years, Pharming Group N.V's Income from Continuing Operations (Yearly) stood at $37.7 million in 2020, then crashed by 118.70% to -$7.1 million in 2021, then spiked by 418.42% to $22.5 million in 2022, then tumbled by 113.90% to -$3.1 million in 2023, then plummeted by 283.16% to -$12.0 million in 2024.